Intercept Pharmaceuticals, Inc. (ICPT)
(Delayed Data from NSDQ)
$89.92 USD
+1.71 (1.94%)
Updated May 3, 2019 04:00 PM ET
After-Market: $89.98 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
[ICPT]
Reports for Purchase
Showing records 581 - 600 ( 867 total )
Industry: Medical - Biomedical and Genetics
Weekly Symphony Health Ocaliva Sales and Volume Estimates
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Industry: Medical - Biomedical and Genetics
Weekly Symphony Health Ocaliva Sales and Volume Estimates
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Industry: Medical - Biomedical and Genetics
ADA Presentation Shows OCA Potency in T2D with NASH
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Industry: Medical - Biomedical and Genetics
Weekly Symphony Health Ocaliva Sales and Volume Estimates
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Weekly Symphony Health Ocaliva Sales and Volume Estimates
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Industry: Medical - Biomedical and Genetics
June and Full Year 2017 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Industry: Medical - Biomedical and Genetics
Weekly Symphony Health Ocaliva Sales and Volume Estimates
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Industry: Medical - Biomedical and Genetics
Weekly Symphony Health Ocaliva Sales and Volume Estimates.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Industry: Medical - Biomedical and Genetics
Weekly Symphony Health Ocaliva Sales and Volume Estimates
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Weekly Symphony Health Ocaliva Sales and Volume Estimates
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Industry: Medical - Biomedical and Genetics
Q1 Update OCA Launch Going Well; Enrollment Complete for REGENERATE Interim Analysis Cohort; Reiterate OUTPERFORM and Raising PT to $231.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Industry: Medical - Biomedical and Genetics
May and Full Year 2017 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of May 1
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Industry: Medical - Biomedical and Genetics
Weekly Symphony Health Ocaliva Sales and Volume Estimates
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Symphony Health Ocaliva Sales and Volume Estimates
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Industry: Medical - Biomedical and Genetics
Weekly Symphony Health Ocaliva Sales and Volume Estimates
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L